Logo image of MYNZ

MAINZ BIOMED NV (MYNZ) Stock Fundamental Analysis

NASDAQ:MYNZ - NL0015000LC2 - Common Stock

1.65 USD
+0.03 (+1.85%)
Last: 8/28/2025, 8:00:02 PM
1.6202 USD
-0.03 (-1.81%)
After Hours: 8/28/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, MYNZ scores 2 out of 10 in our fundamental rating. MYNZ was compared to 547 industry peers in the Biotechnology industry. MYNZ may be in some trouble as it scores bad on both profitability and health. MYNZ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MYNZ has reported negative net income.
MYNZ had a negative operating cash flow in the past year.
In the past 5 years MYNZ always reported negative net income.
MYNZ had a negative operating cash flow in each of the past 5 years.
MYNZ Yearly Net Income VS EBIT VS OCF VS FCFMYNZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

MYNZ has a Return On Assets of -163.55%. This is amonst the worse of the industry: MYNZ underperforms 86.65% of its industry peers.
MYNZ has a worse Return On Equity (-358.07%) than 73.31% of its industry peers.
Industry RankSector Rank
ROA -163.55%
ROE -358.07%
ROIC N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MYNZ Yearly ROA, ROE, ROICMYNZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

MYNZ has a Gross Margin of 64.31%. This is in the better half of the industry: MYNZ outperforms 79.71% of its industry peers.
In the last couple of years the Gross Margin of MYNZ has grown nicely.
MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
MYNZ Yearly Profit, Operating, Gross MarginsMYNZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

2

2. Health

2.1 Basic Checks

MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYNZ has more shares outstanding
The number of shares outstanding for MYNZ has been increased compared to 5 years ago.
MYNZ has a better debt/assets ratio than last year.
MYNZ Yearly Shares OutstandingMYNZ Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
MYNZ Yearly Total Debt VS Total AssetsMYNZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -10.42, we must say that MYNZ is in the distress zone and has some risk of bankruptcy.
MYNZ's Altman-Z score of -10.42 is on the low side compared to the rest of the industry. MYNZ is outperformed by 73.13% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that MYNZ is not too dependend on debt financing.
MYNZ has a worse Debt to Equity ratio (0.14) than 65.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -10.42
ROIC/WACCN/A
WACC6.66%
MYNZ Yearly LT Debt VS Equity VS FCFMYNZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 1.32 indicates that MYNZ should not have too much problems paying its short term obligations.
MYNZ has a worse Current ratio (1.32) than 82.08% of its industry peers.
MYNZ has a Quick Ratio of 1.26. This is a normal value and indicates that MYNZ is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.26, MYNZ is not doing good in the industry: 82.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 1.26
MYNZ Yearly Current Assets VS Current LiabilitesMYNZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

6

3. Growth

3.1 Past

MYNZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.47%, which is quite impressive.
The Revenue has decreased by -0.17% in the past year.
The Revenue has been growing by 26.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.99%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%74.39%

3.2 Future

The Earnings Per Share is expected to grow by 15.04% on average over the next years. This is quite good.
The Revenue is expected to grow by 133.88% on average over the next years. This is a very strong growth
EPS Next Y77.35%
EPS Next 2Y37.51%
EPS Next 3Y23.52%
EPS Next 5Y15.04%
Revenue Next Year4.06%
Revenue Next 2Y4.51%
Revenue Next 3Y37.27%
Revenue Next 5Y133.88%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MYNZ Yearly Revenue VS EstimatesMYNZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
MYNZ Yearly EPS VS EstimatesMYNZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MYNZ Price Earnings VS Forward Price EarningsMYNZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYNZ Per share dataMYNZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as MYNZ's earnings are expected to grow with 23.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.51%
EPS Next 3Y23.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYNZ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAINZ BIOMED NV

NASDAQ:MYNZ (8/28/2025, 8:00:02 PM)

After market: 1.6202 -0.03 (-1.81%)

1.65

+0.03 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-01 2025-04-01/amc
Earnings (Next)09-08 2025-09-08
Inst Owners6.52%
Inst Owner ChangeN/A
Ins Owners1.9%
Ins Owner ChangeN/A
Market Cap7.56M
Analysts82.86
Price Target14.28 (765.45%)
Short Float %2.33%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)40.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.45
P/FCF N/A
P/OCF N/A
P/B 1.25
P/tB 2.49
EV/EBITDA N/A
EPS(TTM)-22.36
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-3.79
FCFYN/A
OCF(TTM)-3.73
OCFYN/A
SpS0.2
BVpS1.32
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -163.55%
ROE -358.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.31%
FCFM N/A
ROA(3y)-154.86%
ROA(5y)-133.82%
ROE(3y)-451.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y27.49%
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.07%
Cap/Sales 28.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 1.26
Altman-Z -10.42
F-Score6
WACC6.66%
ROIC/WACCN/A
Cap/Depr(3y)139.31%
Cap/Depr(5y)92.63%
Cap/Sales(3y)121.7%
Cap/Sales(5y)74.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.99%
EPS Next Y77.35%
EPS Next 2Y37.51%
EPS Next 3Y23.52%
EPS Next 5Y15.04%
Revenue 1Y (TTM)-0.17%
Revenue growth 3Y15.51%
Revenue growth 5Y26.14%
Sales Q2Q%74.39%
Revenue Next Year4.06%
Revenue Next 2Y4.51%
Revenue Next 3Y37.27%
Revenue Next 5Y133.88%
EBIT growth 1Y30.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.1%
OCF growth 3YN/A
OCF growth 5YN/A